Get started
Author

Izabela Chmielewska

Observed names: Chmielewska, Izabela; Department and Clinic of Pulmonology, Oncology and Allergology, Medical University of Lublin, Poland, I Chmielewska, I. Chmielewska
Observed institution: Medical University of Lublin
ORCID: 0000-0002-0948-9071
Observed ORCID: 0000-0002-0948-9071
OpenAlex ID: A5065723854
Mechanisms of aromatase inhibitor resistance
2015 · Cynthia X. Ma, Tomás Reinert, et al. · Nature reviews. Cancer · 407
Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer
2022 · Anna Grenda, Ewelina Iwan, et al. · AMB Express · 65
PDF
LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
2023 · M.C. Garassino, W.S.M.E. Theelen, et al. · Annals of Oncology · 54
PDF
Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer
2025 · Ferdinandos Skoulidis, Bob T. Li, et al. · Nature Medicine · 46
PDF
Attempting to Identify Bacterial Allies in Immunotherapy of NSCLC Patients
2022 · Anna Grenda, Ewelina Iwan, et al. · Cancers · 29
PDF
Effect of Varying Expression of EpCAM on the Efficiency of CTCs Detection by SERS-Based Immunomagnetic Optofluidic Device
2020 · Marta Czaplicka, Krzysztof Niciński, et al. · Cancers · 28
PDF
Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non‐small cell lung cancer patients
2019 · Anna Grenda, Justyna Błach, et al. · Cancer Medicine · 28
PDF
Non-Small-Cell Lung Cancer: New Rare Targets—New Targeted Therapies—State of The Art and Future Directions
2021 · Katarzyna Stencel, Izabela Chmielewska, et al. · Cancers · 26
PDF
First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRAS G12C -mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study.
2025 · Pasi A. Jänne, Willemijn S.M.E. Theelen, et al. · Journal of Clinical Oncology · 25
Blood Serum Calorimetry Indicates the Chemotherapeutic Efficacy in Lung Cancer Treatment
2017 · Karolina Kędra-Królik, Izabela Chmielewska, et al. · Scientific Reports · 24
PDF
Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation
2024 · David M. Waterhouse, Sacha Rothschild, et al. · Lung Cancer · 20
PDF
Neoadjuvant and Adjuvant Immunotherapy in Non-Small Cell Lung Cancer—Clinical Trials Experience
2021 · Izabela Chmielewska, Katarzyna Stencel, et al. · Cancers · 20
PDF
Gut microbial predictors of first-line immunotherapy efficacy in advanced NSCLC patients
2025 · Anna Grenda, Ewelina Iwan, et al. · Scientific Reports · 19
PDF
Impact of copy number variant and single nucleotide polymorphism of the programmed death‑ligand 1 gene, programmed death‑ligand 1 protein expression and therapy regimens on overall survival in a large group of Caucasian patients with non‑small cell lung carcinoma
2021 · Anna Grenda, Paweł Krawczyk, et al. · Oncology Letters · 18
PDF
Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review
2020 · Marta Dudzińska, Michał Szczyrek, et al. · Cancers · 18
PDF
Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients
2021 · Anna Grenda, Paweł Krawczyk, et al. · Frontiers in Oncology · 17
PDF
The influence of plasma sPD-L1 concentration on the effectiveness of immunotherapy in advanced NSCLC patients
2023 · Izabela Chmielewska, Anna Grenda, et al. · Cancer Immunology Immunotherapy · 16
PDF
Radiotherapy(R) Integration(I) Strategy for Small(S)-Cell Lung Cancer in Extensive(E) Stage (RISE) with up to 10 metastases- a study protocol of a randomized phase II trial
2025 · Łukasz Kuncman, Jacek Fijuth, et al. · BMC Cancer · 15
PDF
Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
2021 · Izabela Chmielewska, Marta Dudzińska, et al. · PLoS ONE · 15
PDF
Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutation–Case Report and a Literature Review
2022 · Anna Rekowska, Piotr Rola, et al. · Current Oncology · 14
PDF
Lung Cancer: Spectral and Numerical Differentiation among Benign and Malignant Pleural Effusions Based on the Surface-Enhanced Raman Spectroscopy
2022 · Aneta Aniela Kowalska, Marta Czaplicka, et al. · Biomedicines · 13
PDF
Prognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in second-line immunotherapy for patients with non-small cell lung cancer
2025 · Magdalena Knetki-Wróblewska, Aleksandra Grzywna, et al. · Translational Lung Cancer Research · 12
First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5).
2025 · Saiama Naheed Waqar, Kristof Cuppens, et al. · Journal of Clinical Oncology · 11
8O First-line (1L) datopotamab deruxtecan (Dato-DXd) + durvalumab ± carboplatin in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohorts 2 and 4)
2025 · K. Cuppens, K. Papadopoulos, et al. · ESMO Open · 10
The influence of nutritional status, lipid profile, leptin concentration and polymorphism of genes encoding leptin and neuropeptide Y on the effectiveness of immunotherapy in advanced NSCLC patients
2024 · Małgorzata Frąk, Anna Grenda, et al. · BMC Cancer · 10
PDF
Works count: 100
Citation count: 1,088
H-index: 16
I10-index: 27
Year
Topic
Type